Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients
Authors:
- 9 July 2018
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 25 (8) , 1141-1149
Abstract
Objective: To investigate characteristics of multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients associated with drugs other than natalizumab since our experience in other disease-modifying drugs (DMD) is still limited. Methods: This is a descriptive observational study within the FAERS database, registered between July 2015 and June 2017. Results: The primary cohort for the analysis consisted of 100,921 MS patients (mean (standard deviation (sd)) age, 48.9 (12.8) years, 20.9% male). Among them 786 (0.78%) developed PML. The adjusted odds ratio of PML for each drug was as follows; natalizumab 115.72 (95% CI; 83.83, 159.74), fingolimod 4.98 (3.64, 6.81) followed by dimethyl fumarate 1.77 (1.2, 2.62) and rituximab 3.22 (1.07, 9.72). The median time from the start of suspected drugs to the onset of PML for natalizumab and other agents were 1463 and 178 days, respectively. The proportion of PML appeared higher in Japan (2.4%) compared to that in the United States (0.24%). Conclusion: The reporting proportion of PML was relatively higher in natalizumab followed by fingolimod, dimethyl fumarate and rituximab. Other characteristics of PML associated with DMDs, including the time to onset and differences in reporting among countries, are described.Keywords
This publication has 18 references indexed in Scilit:
- Treatment-related progressive multifocal leukoencephalopathy: current understanding and future stepsTherapeutic Advances in Drug Safety, 2012
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosisNeurology, 2008
- α4Integrins as Therapeutic Targets in Autoimmune DiseaseNew England Journal of Medicine, 2003
- JC Virus-Specific Cytotoxic T Lymphocytes in Individuals with Progressive Multifocal LeukoencephalopathyJournal of Virology, 2001
- Involvement of JC Virus–Infected Mononuclear Cells from the Bone Marrow and Spleen in the Pathogenesis of Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 1988
- Progressive Multifocal Leukoencephalopathy in a Patient With Acquired Immune Deficiency SyndromeArchives of Neurology, 1984
- Neurological complications of acquired immune deficiency syndrome: Analysis of 50 patientsAnnals of Neurology, 1983
- Progressive Multifocal Leukoencephalopathy in a Male Homosexual with T-Cell Immune DeficiencyNew England Journal of Medicine, 1982
- PROGRESSIVE MULTIFOCAL LEUKO-ENCEPHALOPATHYBrain, 1958